Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS: Secukinumab vs Adalimumab Biosimilar in Ankylosing Spondylitis
NCT03259074Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2017
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 29
01
Overview
A Phase 3 trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis. Started Nov 2017; status: completed.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT03259074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03259074.